Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+...
-
Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.
-
American Oncology Network to Participate in 11 Sessions at 2026 Community Oncology Alliance Annual Conference
-
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and...
-
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
-
Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasmaAACR studies demonstrate the...
-
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
-
Drew Woodmansee Board Appointment strengthens Trethera with deep patent expertise and capital formation experience, supporting its next phase of growth.
-
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company...